Clinical Trials - December 9, 2014
Promising Hemophilia Drug
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with hemophilia A who had the highest annualized bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. Data for the recombinant factor VIII (rFVIII) product NovoEight®were presented at the 56th Annual Meeting of the […]
Pharma Business - October 17, 2013
FDA approval of Novo Nordisk’s BLA Novoeight
Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) have approved its Biologics License Application (BLA) for recombinant coagulation factor VIII, Novoeight. The FDA approved Novoeight for use in adults and children with haemophilia A for control and prevention of bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency […]
